PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2419845

Noninvasive conversion of atrial flutter using a multiprogrammable DDD pulse generator.

R M Luceri·A Castellanos·R J Thurer·R J Myerburg
View original source ↗Export metadata ↓

Abstract

A patient with sick sinus syndrome and resistant paroxysmal atrial flutter was treated with amiodarone and implanted with a Medtronic 7005 DDD pacemaker. Following discontinuation of amiodarone, an episode of sustained atrial flutter was converted to sinus rhythm by noninvasive rapid atrial pacing in the outpatient clinic. This case illustrates one of the many capabilities for arrhythmic intervention using currently available implanted pacemakers.

Explore related subjects

AmiodaroneAtrial FlutterCombined Modality TherapyElectrocardiographyHeart BlockHeart RateHumansMaleMiddle AgedPacemaker, ArtificialCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R M Luceri, A Castellanos, R J Thurer, R J Myerburg. 1986. Noninvasive conversion of atrial flutter using a multiprogrammable DDD pulse generator.. https://doi.org/10.1111/j.1540-8159.1986.tb05372.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study.

OBJECTIVES: The goal of this study was to evaluate the effect of amiodarone on mortality, ventricular arrhythmias and clinical complications in high risk postinfarction patients. BACKGROUND: No therapy has been shown to reduce sudden death in patients ineligible to receive beta-adrenergic blocking agents after myocardial infarction. METHODS: Patients who were not eligible to receive beta-blockers were randomized to receive amiodarone (n = 305) or placebo (n = 308) for 1 year. RESULTS: There were 21 deaths in the amiodarone group compared with 33 in the placebo group (odds ratio 0.62, 95% confidence interval [CI] 0.35 to 1.08, p = 0.095). There were two noncardiac deaths in the amiodarone group and none in the placebo group; thus, the difference in cardiac mortality (19 vs. 33, respectively) was statistically significant (odds ratio 0.55, 95% CI 0.32 to 0.99, p = 0.048). There was a significant decrease in Lown class 4 ventricular arrhythmias (7.5% vs. 19.7%, respectively, p < 0.001). Adverse effects developed in 30% of amiodarone-treated patients and 10% of placebo-treated patients. Pulmonary toxicity, which was mild and reversible, occurred in only one patient in the amiodarone group but in no patient in the placebo group. CONCLUSIONS: This trial demonstrated a significant reduction in cardiac mortality and ventricular arrhythmias with amiodarone treatment. However, given the wide confidence intervals and borderline statistical significance of our trial, larger trials are needed to confirm or refute this view.

Amiodarone↗